Which pharma companies will benefit from latest government policies? Sumit Gupta explains

economictimes.indiatimes.com:

Sumit Gupta, AVP-Research, Centrum Broking, says the government is providing a push towards manufacturing and R&D. Indian pharma has technical know-how. Now, the government wants to do technical ‘know-why’. Say Indian companies are currently doing CDMO manufacturing for MNC players. The government wants us to do R&D, build on some basically blockbuster drugs and then outsource that to some other countries. In one of your recent reports, you say that the government policies are expected to aid the long-term growth of the pharma space. The government is focusing on the R&D side, they are focusing on building and promoting bulk drug parks. How do you see the domestic companies benefit out of the same and amongst this whole sector, which particular segment is expected to benefit the most?
Sumit Gupta: The government is focusing on promoting R&D and manufacturing in the pharmaceutical sector and these policies will be catering to or helping the overall sector for the medium to long term. So, the policies like bulk drug parks or the PLI for the pharma scheme or PLI for manufacturing critical APIs, drug intermediaries and KSMs or PLL for medtech. These are some of the sectors which are expected to benefit from government schemes.

The government is providing a push towards manufacturing and R&D. Indian pharma has technical know-how. However, the government wants to do technical ‘know-why’. Say we are currently doing CDMO manufacturing for MNC players. The government wants us to do R&D, build on some basically blockbuster